What is Glyxambi?

Glyxambi is a brand-name medication that consists of two separate drugs, empagliflozin and linagliptin. The Glyxambi drug class is antidiabetic combination, which means it combines two drugs of different classes. The two drug classes in the combination are SGLT-2 inhibitor (empagliflozin) and DPP-4 inhibitor (linagliptin). Glyxambi is distributed by two drug manufacturers, Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company.

What is this medication used for?

Glyxambi is used to treat type 2 diabetes in adults when treatment with both empagliflozin and linagliptin is possible. It is used in combination with diet and exercise to increase glycemic control in adults with the condition. Empagliflozin and linagliptin work together to improve glucose levels in the blood. Empagliflozin helps the kidneys rid the bloodstream of glucose, while linagliptin helps regulate the levels of insulin produced by the body after eating.

Glyxambi is also used to help lower the risk of complications leading to death, such as heart attack, stroke, or heart failure, in adults who have type 2 diabetes and heart disease. This medication is not suitable for treating type 1 diabetes.

How to take this drug

Glyxambi should be taken as it is prescribed to you by your doctor. It is taken orally, typically in the morning, with or without food. It is important to regularly check your blood sugar levels while taking Glyxambi, as well as the levels of ketones in your urine.

Glyxambi side effects

Glyxambi has been proven to be safe and effective through clinical studies. However, there are some side effects associated with its use. If you experience any severe side effects, stop taking the medication and contact your doctor. This is not a complete list of side effects.

Common side effects

  • Urinary tract infection
  • Nausea
  • Diarrhea
  • Cold-like symptoms (cough, runny or stuffy nose, etc.)

Severe side effects

  • Severe pain in the upper stomach spreading to the back
  • Vomiting
  • Dizziness
  • Fast heart rate


The initial dosage of Glyxambi is 10 mg of empagliflozin and 5 mg of linagliptin, taken once a day. Patients who are tolerating the therapy may increase their dosage to 25 mg of empagliflozin and 5 mg of linagliptin, taken once a day.

The maximum dosage of Glyxambi a patient should take is 25 mg of empagliflozin and 5 mg of linagliptin. If the patient is also taking insulin or insulin secretagogues, the patient may need to adjust to a lower dosage of the insulin or insulin secretagogues.


Disclaimer: Please note that the contents of this community article are strictly for informational purposes and should not be considered as medical advice. This article, and other community articles, are not written or reviewed for medical validity by Canadian Insulin or its staff. All views and opinions expressed by the contributing authors are not endorsed by Canadian Insulin. Always consult a medical professional for medical advice, diagnosis, and treatment.